Evaxion Announces Initial Phase 2 Clinical Data On Its Personalized Cancer Vaccine EVX-01
Portfolio Pulse from Benzinga Newsdesk
Evaxion Biotech A/S (NASDAQ:EVAX) has announced initial results from the EVX-01 Phase 2 clinical trial, confirming previous successful Phase 1 findings. The data shows a favorable safety profile of EVX-01 and promising immunological and clinical outcomes. A significant tumor reduction was observed in a metastatic melanoma patient with initial progressive disease after EVX-01 treatment. The company believes that its AI-Immunology™ platform has the potential to revolutionize the field of oncology and infectious diseases.
October 31, 2023 | 3:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evaxion's successful initial Phase 2 results for EVX-01 could boost investor confidence in the company's AI-Immunology™ platform and its potential in oncology and infectious diseases.
The successful initial Phase 2 results for EVX-01 confirm the previous Phase 1 findings, which could increase investor confidence in Evaxion's AI-Immunology™ platform and its potential to revolutionize the field of oncology and infectious diseases. This could potentially lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100